PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 5, 2014, Pages 550-557

  Vieira, M D L T ^a   Kim, M J ^a   Apparaju, S ^a   Sinha, V ^a   Zineh, I ^a   Huang, S M ^a   Zhao, P ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FESOTERODINE; FLUCONAZOLE; FLUVOXAMINE; ILOPERIDONE; ITRACONAZOLE; KETOCONAZOLE; PAROXETINE; QUINIDINE; RISPERIDONE; TOLTERODINE;

ACCURACY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; HYPERMETABOLISM; MAXIMUM PLASMA CONCENTRATION; MODEL; PHARMACOKINETIC MODEL; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL;

CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 84899442309     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.43     Document Type: Article

References (41)

1. Rowland, M., Peck, C. & Tucker, G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51, 45-73 (2011).
2. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259-267 (2011).
3. Zhao, P., Rowland, M. & Huang, S.M. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin. Pharmacol. Ther. 92, 17-20 (2012).
4. Huang, S.M., Abernethy, D.R., Wang, Y., Zhao, P. & Zineh, I. The utility of modeling and simulation in drug development and regulatory review. J. Pharm. Sci. 102, 2912-2923 (2013).
5. Benet, L.Z., Broccatelli, F. & Oprea, T.I. BDDCS applied to over 900 drugs. AAPS J. 13, 519-547 (2011).
6. Gertz, M., Houston, J.B. & Galetin, A. Physiologically based pharmacokinetic modeling of intestinal frst-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab. Dispos. 39, 1633-1642 (2011).
7. Guest, E.J., Aarons, L., Houston, J.B., Rostami-Hodjegan, A. & Galetin, A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab. Dispos. 39, 170-173 (2011).
8. Wang, Y.H. Confdence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors. Drug Metab. Dispos. 38, 1094-1104 (2010).
9. Youdim, K.A. et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br. J. Clin. Pharmacol. 65, 680-692 (2008). (Pubitemid 351535079)
10. Fahmi, O.A. et al. Comparison of diferent algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab. Dispos. 37, 1658-1666 (2009).
11. Vieira, M.L. et al. Evaluation of Various Static In Vitro-In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug. Clin. Pharmacol. Ther. 95, 189-198 (2014).
12. Vanda Pharmaceuticals. FANAPT™ (iloperidone) tablets-Prescribing Information. 〈http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 022192lbl.pdf〉 (2009).
13. Ortho-McNeil-Janssen Pharmaceuticals. RISPERDAL®(risperidone) Tablets- Prescribing Information. 〈http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/020272s056, 020588s044, 021346s033, 021444s03lbl.pdf〉 (2009).
14. Pfzer. Toviaz® (fesoterodine fumarate)-Prescribing Information. 〈http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022030s009lbl. pdf〉 (2012).
15. Vieira, M.L. et al. Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. Clin. Pharmacol. Ther. 91, 700-708 (2012).
16. Yee, G.C. & McGuire, T.R. Pharmacokinetic drug interactions with cyclosporin (Part I). Clin. Pharmacokinet. 19, 319-332 (1990). (Pubitemid 20283428)
17. Gomes, T., Mamdani, M.M. & Juurlink, D.N. Macrolide-induced digoxin toxicity: a population-based study. Clin. Pharmacol. Ther. 86, 383-386 (2009).
18. Fleishaker, J.C. & Hulst, L.K. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fuvoxamine. Eur. J. Clin. Pharmacol. 46, 35-39 (1994). (Pubitemid 24067586)
19. Lam, Y.W., Alfaro, C.L., Ereshefsky, L. & Miller, M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fuoxetine, fuvoxamine, and nefazodone. J. Clin. Pharmacol. 43, 1274-1282 (2003). (Pubitemid 37280799)
20. von Moltke, L.L., Greenblatt, D.J., Court, M.H., Duan, S.X., Harmatz, J.S. & Shader, R.I. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fuvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychopharmacol. 15, 125-131 (1995).
21. Bowles, S.K., Reeves, R.A., Cardozo, L. & Edwards, D.J. Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine. J. Clin. Pharmacol. 33, 727-731 (1993). (Pubitemid 23260399)
22. von Moltke, L.L. et al. Triazolam biotransformation by human liver microsomes in vitro: efects of metabolic inhibitors and clinical confrmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther. 276, 370-379 (1996). (Pubitemid 126660470)
23. Galetin, A., Clarke, S.E. & Houston, J.B. Quinidine and haloperidol as modifers of CYP3A4 activity: multisite kinetic model approach. Drug Metab. Dispos. 30, 1512-1522 (2002). (Pubitemid 35397061)
24. Yao, C., Kunze, K.L., Trager, W.F., Kharasch, E.D. & Levy, R.H. Comparison of in vitro and in vivo inhibition potencies of fuvoxamine toward CYP2C19. Drug Metab. Dispos. 31, 565-571 (2003). (Pubitemid 36444165)
25. Ke, A.B., Nallani, S.C., Zhao, P., Rostami-Hodjegan, A., Isoherranen, N. & Unadkat, J.D. A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metab. Dispos. 41, 801-813 (2013).
26. Zhou, S.F. Polymorphism of human cytochrome P450 2D6 and its clinical signifcance: Part I. Clin. Pharmacokinet. 48, 689-723 (2009).
27. Yang, Z. et al. Inhibitory efect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations. J. Clin. Pharmacol. 53, 217-227 (2013).
28. Altamura, A.C., Moro, A.R. & Percudani, M. Clinical pharmacokinetics of fuoxetine. Clin. Pharmacokinet. 26, 201-214 (1994).
29. Bergstrom, R.F., Peyton, A.L. & Lemberger, L. Quantifcation and mechanism of the fuoxetine and tricyclic antidepressant interaction. Clin. Pharmacol. Ther. 51, 239-248 (1992).
30. DeVane, C.L, et al. Comparative CYP3A4 inhibitory efects of venlafaxine, fuoxetine, sertraline, and nefazodone in healthy volunteers. J. Clin. Psychopharmacol. 24, 4-10 (2004).
31. Wang, Y.H., Jones, D.R. & Hall, S.D. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab. Dispos. 32, 259-266 (2004). (Pubitemid 38176944)
32. Otsuka Pharmaceuticals. NDA 21-436-Aripiprazole-Abilify™-Clinical Pharmacology and Biopharmaceutics Review. 〈http://www.accessdata.fda. gov/drugsatfda-docs/nda/2002/21-436-Abilify.cfm〉 (2002).
33. Kubo, M. et al. Infuence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Drug Metab. Pharmacokinet. 20, 55-64 (2005).
34. Azuma, J. et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: efects of CYP enzyme inhibition by coadministration of paroxetine or fuvoxamine. Eur. J. Clin. Pharmacol. 68, 29-37 (2012).
35. Pfzer. NDA 22-030-Fesoterodine fumarate-Toviaz™-FDA Drug Approval Package. 〈http://www.accessdata.fda.gov/drugsatfda-docs/nda/2008/ 022030s000TOC.cfm〉 (2008).
36. Malhotra, B., Darsey, E., Crownover, P., Fang, J. & Glue, P. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. Br. J. Clin. Pharmacol. 72, 226-234 (2011).
37. Malhotra, B. et al. Efects of the moderate CYP3A4 inhibitor, fuconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br. J. Clin. Pharmacol. 72, 263-269 (2011).
38. Vanda Pharmaceuticals. NDA 022192-Iloperidone-Fanapt™-FDA Drug Approval Package. 〈http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/ 022192s000TOC.cfm〉 (2009).
39. Mahatthanatrakul, W. et al. Efect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers. J. Clin. Pharm. Ther. 37, 221-225 (2012).
40. Bondolf, G., Eap, C.B., Bertschy, G., Zullino, D., Vermeulen, A. & Baumann, P. The efect of fuoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 35, 50-56 (2002). (Pubitemid 34293233)
41. Otsuka Pharmaceuticals and Bristol-Myers Squibb. Abilify ® (aripiprazole) Tablets, Oral solution, Injection for intramuscular use only-Prescribing Information. 〈http://www.accessdata.fda.gov/drugsatfda- docs/label/2011/021436s032, 021866s019, 021713s024, 02172 9s017lbl.pdf〉 (2011).